Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Biogaia Adr Class B BIOGY

Biogaia AB is a Sweden-based healthcare company that is engaged in the development and sell of probiotic products. The Company develops, markets and sells probiotic products with documented health benefits. The products are primarily based on different strains of the lactic acid bacterium Limosilactobacillus reuteri. The Company’s activities are divided into three segments: The Paediatrics... see more

Recent & Breaking News (PINL:BIOGY)

BrainStorm Enters Into Warrant Exercise Agreement for Approximately $13 Million in Proceeds

PR Newswire January 8, 2015

Aerix To Extend Availability Of DTS Play-Fi® Wireless Whole Home Audio Ecosystem To Europe

PR Newswire January 8, 2015

TRVX: Targovax Reports Completion of Recruitment of Patients in the Phase I/II Clinical Trial CT TG01-01

Business Wire January 8, 2015

Research and Markets: Cloud Market In Healthcare Technologies - Global Trends, Challenges, Opportunities & Forecasts to 2020

Business Wire January 8, 2015

PharmaCyte Biotech Announces Update on Corporate Changes

GlobeNewswire January 8, 2015

Avalanche Biotechnologies Prices Public Offering of $141.6 Million of Common Stock

GlobeNewswire January 8, 2015

Jounce Therapeutics Appoints Deborah Law, D.Phil., to Chief Scientific Officer

Business Wire January 8, 2015

CytRx Announces Positive Interim Phase 2 Aldoxorubicin Results as a Treatment for HIV-Related Kaposi's Sarcoma (KS)

PR Newswire January 8, 2015

Research and Markets: Agriculture Equipment and Self-propelled Equipment Markets Report - Global Forecasts to 2019 Featuring Key Players, Deere & Company, CNH Global NV & AGCO Manufacturing Company

Business Wire January 8, 2015

Sustained Release Injectables to 2022

PR Newswire January 8, 2015

Biocept and Insight Genetics Collaborate to Advance Non-Small Cell Lung Cancer Diagnosis and Treatment

GlobeNewswire January 8, 2015

Chimerix Provides Update on Brincidofovir Pivotal Phase 3 AdVise Trial for the Treatment of Adenovirus

GlobeNewswire January 8, 2015

Aeolus Announces Response to FDA Clinical Hold and Plan for Clinical Development of AEOL 10150

Marketwired January 8, 2015

Regen BioPharma Inc. Identifies Second Generation Gene Silencing Candidates for Blocking Cancer Stem Cell Gene Target

Marketwired January 8, 2015

Infectious Disease Diagnostics Market Worth $18,156.2 Million by 2019

PR Newswire January 8, 2015

Ceapro to Present at the Eighth Annual OneMedForum on Tuesday, January 13, 2015

Marketwired January 8, 2015

Xenon Pharmaceuticals Outlines Key Anticipated Milestones for 2015

GlobeNewswire January 8, 2015

Merrimack Pharmaceuticals Announces Oral Presentation of Additional Analyses of MM-398 Phase 3 NAPOLI-1 Study at the American Society of Clinical Oncology (ASCO) 2015 Gastrointestinal Cancers Symposium

GlobeNewswire January 8, 2015

Cellular Biomedicine Group to Present at OneMedForum and BioTech Showcase in San Francisco

GlobeNewswire January 8, 2015

Alacrita Strengthens Cambridge, MA Team to Advise Clients on Clinical Development Strategy, Planning and Operations

PR Newswire January 8, 2015